|Bid||145.00 x 100|
|Ask||153.00 x 400|
|Day's Range||144.59 - 150.17|
|52 Week Range||36.71 - 192.94|
|PE Ratio (TTM)||-17.21|
|Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
It hasn't been a great year so far for Opko Health, but the future could be brighter.
Tesaro's Zejula would likely outperform drugs from Clovis and AstraZeneca in immuno-oncology combinations with Merck, Bristol or Roche.
The biotechnology-stock rally continues. The SPDR S&P Biotech (XBI) and the iShares Nasdaq Biotechnology (IBB), among the highest-flying exchange-traded funds yesterday, both hit their 52-week highs on ...